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Abstract Triple-negative breast cancer (TNBC) refers to
about 15–20 % of all breast cancer cases. It is characterized
by worse clinical outcome, poor prognosis, and absence of
prognostic indicators. Several polymorphisms in the nucleo-
tide excision repair (NER) and base excision repair (BER)
gene have been extensively studied in association with various
human cancers. The aim of this study was to evaluate the role
of the hOGG1 -Ser326Cys (rs13181), XRCC1 -Arg194Trp
(rs1799782), and ERCC2 -Lys751Gln (rs13181) gene
polymorphisms with clinical parameters and the risk for devel-
opment of triple-negative breast cancer. Our research included
70 patients with TNBC and 70 healthy controls. Gene poly-
morphisms were genotyped by the PCR-RFLP (restriction
fragment length polymorphism) method. The genotype distri-
butions were contrasted by the chi-square test, and the signifi-
cance of the polymorphism was assessed by multiple logistic
regression producing odds ratios (ORs) and 95 % confidence
intervals (CIs). In the present work, a relationshipwas identified
between ERCC2-Lys751Gln polymorphism and the incidence
of triple-negative breast cancer. An association was observed
between triple-negative breast carcinoma occurrence and the
presence of Gln/Gln genotype (OR=5.71 (2.12–5.43), p =
0.0007). A tendency for an increased risk of TNBCwas detect-
ed with the occurrence of 751Gln allele of ERCC2 polymor-
phism. No significant associations between Ser326Cys and
Arg194Trp genotype and TNBC were observed. We suggest
that the Lys751Gln polymorphism of the ERCC2 gene may be
risk factors for triple-negative breast cancer development in
Polish women.
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Introduction
Carcinoma of the breast is the most common cause of cancer
deaths among women worldwide. Despite a decline in inci-
dence since 2003, in 2008, nearly 1,400,000 new cases of
breast cancer were diagnosed, and there were about 450,000
women who died from this disease [1, 2].
Currently, more women survive due to earlier diagnosis
and better therapy. Breast cancer classification is in constant
evolution, as advances in molecular pathology as well as
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immunohistochemical staining allow researchers to define the
molecular heterogeneity of different disease subtypes and to
guide the selection of appropriate treatment.
The triple-negative phenotype, defined as the lack of
estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor-2 (HER-2) expres-
sion, represents approximately 15–20 % of breast cancer
cases and has a worse clinical outcome and prognosis than
other breast cancer subtypes [2–6]. As a group, triple-
negative breast cancer (TNBC) is frequently associated with
development of distant metastasis, shorter survival, and a
higher mortality rate than other disease subtypes. Most
recurrences are observed during the first and third years
after therapy, and most deaths take place in the first 5 years,
even after a strict therapeutic regimen. The triple negativity
represents an independent factor for poor prognosis evalu-
ation for breast cancer [2–6].
Breast cancer may be associated with the high exposure of
breast tissue to exo- and endogenous estrogens. Estrogens
produce DNA bulky adducts and oxidative base damages
which are removed in nucleotide excision repair (NER) and
base excision repair (BER) systems. The reaction of breast
cells to DNA damage may be very important for their suscep-
tibility to cancer development. This reaction is executed main-
ly by DNA repair, which can be modulated by the variability
in the genes encoding DNA repair proteins.
A NER system removes short DNA oligonucleotides con-
taining a damaged base [7]. NER recognizes bulky lesions
caused by carcinogenic compounds and covalent linkages
between adjacent pyrimidines resulting from UV exposure.
NER is further classified into global genome repair (GG-
NER) that occurs everywhere in the genome and
transcription-coupled repair (TCR), which removes lesions
in the transcribed strand of active genes. NER is a multistep
process involving multiple proteins such as ERCC1, ERCC2 ,
ERCC3, ERCC4, PCNA, RPA, XPA, and p53.
BER is critically important for repairing base damage
induced by reactive oxygen species (ROS). BER corrects
small DNA alterations that do not distort the overall structure
of DNA helix, such as oxidized bases, or incorporation of
uracil. BER is initiated by DNA glycosylases, which cleave
N-glycosylic bond of damaged bases leaving apurinic/
apyrimidinic site (AP site) [8, 9].
A damaged base is recognized by a specific glycosylase,
which cleaves the bond between the base and sugar, creating
an abasic site, which is cleaved by an endonuclease. Resulting
gap is filled by polβ, and the remaining nick is sealed byDNA
ligase LIG1 or LIG3 complexed with XRCC1.
Because NER and BER are involved in removing a sub-
stantial number of DNA damages, which can contribute to the
genome instability, it is reasonable to check whether variabil-
ity in the genes coding for BER and NER products may be
associated with TNBC.
In the present work, we analyzed an association between
TNBC and three SNPs occurring in two BER and NER genes:
hOGG1 -Ser326Cys (rs13181), XRCC1-Arg194Trp
(rs1799782) and ERCC2 -Lys751Gln (rs13181), respectively.
These polymorphisms have been correlated with various can-




In the present study, paraffin-embedded tumor tissues were
obtained from 70 women with triple-negative breast carcino-
ma, treated at the Department of Oncology, Institute of Polish
Mother's Memorial Hospital, Lodz, Poland, between 2000 and
2013. Clinical data for the patients and histological data were
registered. The age of the patients ranged from 36 to 68 years
(mean age 46.2±10.12). The median follow-up of patients at
the time of analysis was 38 months (range 2–70 months). The
average tumor size was 20 mm (range 17–32 mm). All the
tumors were graded by a method, based on the criteria of
Scarf–Bloom–Richardson. There were 20 tumors of stage I,
45 of stage II, and 5 of stage III in total. The demographic data
and the pathologic features of the patients are summarized in
Table 1. Samples from age-matched, cancer-free women (n =
70) served as the control (mean age 45.41±18.21). Control
samples that consisted of DNA were extracted from normal
breast tissue. Normal breast specimens were obtained from
Table 1 Characteristics of the study population (n=70) triple-negative
breast cancer patients
Triple-negative breast
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patients who had undergone biopsy for benign lesions. The
study was approved by the Local Ethics Committee of the
Institute of Polish Mother's Memorial Hospital, Lodz, Poland,
and each patient gave a written consent.
DNA isolation
The cancerous and noncancerous breast tissue samples were
fixed routinely in formaldehyde, embedded in paraffin, cut into
thin slices, and stained with hematoxylin/eosin for pathological
examination. DNA for analysis was obtained from an archival
pathological paraffin-embedded tumor and noncancerous breast
samples whichwere deparaffinized in xylene and rehydratated in
ethanol and distilled water. In order to ensure that the chosen
histological material is representative for cancerous and noncan-
cerous tissue, every tissue sample qualified for DNA extraction
was initially checked by a pathologist. DNAwas extracted from
the material using commercially available QIAamp Kit (Qiagen
GmbH, Hilden, Germany) DNA purification kit according to the
manufacturer's instruction.
Determination of ERCC2 genotype
Polymorphism Lys751Gln of the ERCC2 gene was deter-
mined by PCR-RFLP, using primers (forward 5′-CTGCTC
AGCCTGGAGCAGC-3′ and reverse 5′-ACTGTCACTAGT
CTCACCAG-3′). The PCRwas carried out in a PTC-100 TM
(MJ Research, INC) thermal cycler. PCR amplification was
performed in the final volume of 25 μl of reaction mixture,
which contained 100 ng of genomic DNA, 0.2 μmol of each
primer (ARK Scientific GmbH Biosystems, Darmstad, Ger-
many), 2.5 mM of MgCl2, 1 mM of dNTPs, and 1 U of Taq
polymerase (Qiagen GmbH, Hilden, Germany). PCR cycle
conditions were the following: 95 °C for 30 s, 62 °C for 30 s,
and 72 °C for 30 s, repeated in 35 cycles. PCR products were
electrophoresed in a 2 % agarose gel and visualized by
ethidium bromide staining. The cleavage with Pst I
(Fermentas, Vilnius, Lithuania) produced fragments of 161,
161/120/41, and 120/41 bp corresponding to the Lys/Lys, Lys/
Gln, and Gln/Gln genotypes of the ERCC2 gene, respectively.
Determination of hOGG1 genotype
Polymorphism Ser326Cys of the hOGG1 gene was deter-
mined by PCR-RFLP, using primers (5′-GGAAGGTGCT
TGGGGAAT-3′ and 5′-ACTGTCACTAGTCTCACCAG-
3′). The 25-μL PCR mixture contained about 100 ng of
DNA, 12.5 pmol of each primer, 0.2 mmol/L of dNTPs,
2 mmol/L of MgCl2, and 1 U of Taq DNA polymerase. PCR
products were electrophoresed in a 2 % agarose gel and
visualized by ethidium bromide staining. Only one 100-bp
fragment was seen in subjects with the Cys/Cys genotype. In
subjects with the Ser/Cys genotype, two bands of 100 and
200 bp were seen, whereas in those subjects homozygous for
the Ser variant (Ser/Ser), only one 200-bp PCR fragment is
seen. All PCR was carried out in a DNA thermal cycler
(GeneAmp PCR System 2400; Perkin-Elmer, Norwalk, CT,
USA). After an initial denaturation at 95 °C for 5 min, 35 cy-
cles of amplification with denaturation at 95 °C for 30 s,
annealing at 56 °C for 30 s, and extension at 72 °C for 30 s
were performed, followed by a final extension step of 7 min at
72 °C. The PCR product was digested overnight with 1 U of
SatI (Fermentas, Vilnius, Lithuania) at 37 °C.
Determination of XRCC1 genotype
Polymorphism Arg194Trp of the XRCC1 gene was determined
by PCR-RFLP, using primers (forward 5′-GCCCGTCCCAGG
TA-3′, reverse 5′-AGCCCCAAGACCCTTTCACT-3′).
The PCR was carried out in a PTC-100 TM (MJ Research,
Inc.) thermal cycler. PCR amplification was performed in the
final volume of 25 μl of reaction mixture, which contained
100 ng of genomic DNA, 0.2 μmol of each primer (ARK
Scientific GmbH Biosystems, Darmstad, Germany), 2.5 mM
of MgCl2, 1 mM of dNTPs, and 1 U of Taq Polymerase
(Qiagen GmbH, Hilden, Germany). PCR cycle conditions
were the following: 95 °C for 30 s, 62 °C for 30 s, and
72 °C for 40 s, repeated in 35 cycles. After digestion with
Pvu II (New England Biolabs, Ipswich, MA, USA) for 4 h at
37 °C, the samples were run on 2% agarose gel and visualized
by ethidium bromide staining. The cleavage of the XRCC1
fragment with Pvu II (New England Biolabs, Ipswich, MA,
USA) produced bands of 292/174/21, 313/292/174/21, and
313/174 bp corresponding to the Arg/Arg, Arg/Trp, and Trp/
Trp genotypes, respectively.
Statistical analysis
The allelic frequencies were estimated by gene counting, and the
genotypes were scored. The observed numbers of each hOGG1 ,
XRCC1 , and ERCC2 genotype were compared with those ex-
pected for a population inHardy–Weinberg equilibrium by using
the chi-square test. Genotype frequencies in the study cases and
the controls were compared by the chi-square test. Genotype-
specific risks were estimated as odds ratios (ORs) with associat-
ed 95 % confidence intervals (CIs) by unconditional logistic
regression. p values<0.05 were considered significant. All the
statistical analyses were performed, using the STATISTICA 6.0
software (Statsoft, Tulsa, OK, USA).
Results
All the recruited TNBC samples (n =70) and control (n =70)
were successfully genotyped for the ERCC2 , hOGG1 , and
XRCC1 polymorphisms. From the PCR analysis, all patients
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were classified into three genotypes of the ERCC2 polymor-
phism: Lys/Lys, Lys/Gln and Gln/Gln, and hOGG1 polymor-
phism; Ser/Ser, Ser/Cys and Cys/Cys, and XRCC1 polymor-
phism; and Arg/Arg, Arg/Trp, and Trp/Trp genotypes.
It can be seen from Table 2 that there are significant
differences in the frequency of ERCC2-Lys751Gln genotypes
(p <0.05) between the two investigated groups. Aweak asso-
ciation was observed between triple-negative breast carcino-
ma occurrence and the presence of Gln/Gln genotypes. Variant
751Gln allele of ERCC2 increased cancer risk. In case of the
Lys751Gln polymorphism of ERCC2 gene, the distribution of
the genotypes in the patients differed significantly from the
one expected from the Hardy–Weinberg equilibrium (p <
0.05).
No statistically significant differences were observed in
genotype frequencies of hOGG1-Ser326Cys and XRCC1-
Arg194Trp polymorphisms between the control group and
the TNBC patients (see Tables 3 and 4). Among the patients,
all genotype distributions did not differ significantly (p >0.05)
from those expected from the Hardy–Weinberg equilibrium.
Histological grading was related to ERCC2-Lys751Gln,
hOGG1-Ser326Cys, and the XRCC1 -Arg194Trp polymor-
phisms. Histological stages were evaluated in all the cases
(n =70). There were 20 cases in stage I, 45 cases in stage II,
and 5 cases in stage III. Stages II and III were accounted
together for statistical analysis (see Table 5). No differences
were observed in those groups regarding either
ERCC2-Lys751Gln genotype or allele distributions. Some
correlation was observed between the hOGG1-Ser326Cys
and XRCC1 -Arg194Trp polymorphisms and TNBC invasive-
ness. An increase was observed regarding Ser/Cys heterozy-
gotes frequency (OR 2.42; 95 % CI 0.58–9.99, p =0.177) and
Arg/Trp heterozygotes (OR 1.89; 95 % CI 0.54–6.57, p =
0.479) in stage I patients, according to the Scarf–Bloom–
Richardson classification. That increase was, however, not
statistically significant (p >0.05).
Table 6 shows the distribution of genotypes and the fre-
quency of alleles in patients with different tumor size. A
tendency for an increased risk of TNBC was observed with
the occurrence of 751Gln allele of ERCC2 polymorphism.
That increase was statistically significant (p <0.05). There
were no differences either in the distribution of genotypes or
the frequency of alleles in the group of patients with (N+) and
without (N−) lymph node metastases (Table 6).
Discussion
The aim of the present study was to evaluate the associations
between the risk of TNBC and polymorphisms in the genes,
Table 2 Distribution of Lys/Lys, Lys/Gln, and Gln/Gln genotypes and frequencies of the Lys and Gln alleles of the ERCC2 gene in patients with triple-
negative breast cancer and controls
ERCC2-Lys751Gln TNBC patients (n=70) Controls (n =70) OR (95 % CI)a pb
Number (%) Number (%)
Lys/Lys 10 14 16 23 1.00 Ref
Lys/Gln 10 14 40 57 0.40 (0.14–1.14) 0.144
Gln/Gln 50 72 14 20 5.71 (2.12–5.34) 0.0007
Lys 30 21 72 51 1.00 Ref
Gln 110 79 68 49 3.88 (2.30–6.55) <0.0001
Data in boldface are statistically significant
a Crude odds ratio (confidence interval at 95 %)
b Chi-square
Table 3 Distribution of Ser/Ser,
Ser/Cys, and Cys/Cys genotypes
and frequencies of the Arg and
His alleles of the hOGG1 gene in
patients with triple-negative
breast cancer and controls
a Crude odds ratio (confidence
interval at 95 %)
b Chi-square
hOGG1-Ser326Cys TNBC patients (n =70) Controls (n =70) OR (95 % CI)a pb
Number (%) Number (%)
Ser/Ser 16 23 16 23 1.00 Ref
Ser/Cys 39 56 38 54 1.02 (0.45–2.34) 0.888
Cys/Cys 15 21 16 23 0.93 (0.34–2.51) 0.887
Ser 71 51 70 50 1.00 Ref
Cys 69 49 70 50 0.97 (0.60–1.55) 1.000
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encoding for key proteins of BER and NER. In the present
work, we analyzed three single nucleotide polymorphisms of
the XRCC1 , hOGG1 , and ERCC2 DNA repair genes and
tested the association between the distributions of their geno-
types with TNBC.
ERCC2 -Lys751Gln, hOGG1 -Ser326Cys, and the
XRCC1 -Arg194Trp polymorphisms have been shown to have
functional significance and may be in part responsible for the
interindividual difference in capacity of DNA repair in the
general population and for low DNA repair efficacy in pa-
tients with various cancers [25–28].
In the presented study, ERCC2 -Gln/Gln genotype was
associated with an elevated risk of TNBC in the Polish pop-
ulation. There was a 5.71-fold increased risk of TNBC for
ERCC2 -Gln/Gln genotype carriers, compared with subjects
with the ERCC2 -Lys/Lys and Lys/Gln genotypes, respective-
ly. We have also found that ERCC2- Lys751Gln
polymorphism was related to tumor size. This result may
suggest major contribution of the Lys751Gln polymorphism
of the ERCC2 gene in cancer development, but more studies
performed on larger population are needed to draw a final
conclusion.
It is known that the Gln/Gln homozygous variant of the
ERCC2 gene has been associated with an increased risk of
lung, skin, bladder, and breast cancer [20, 21, 29, 30].
The role of ERCC2 -Lys751Gln polymorphisms and breast
cancer development is still unknown. To date, no studies have
addressed the association between alterations in this region of
the ERCC2 gene and TNBC. Because a proper functioning of
the ERCC2 gene is important for the genomic stability, its
alternations may be associated with higher cancer
susceptibility.
Breast cancer is estrogen related. Estrogen mediates cellu-
lar growth and differentiation in tissues such as the mammary
Table 4 Distribution of Arg/Arg,
Arg/Trp, and Trp/Trp genotypes
and frequencies of the Thr and
Met alleles of the XRCC1 gene in
patients with triple-negative
breast cancer and controls
a Crude odds ratio (confidence
interval at 95 %)
b Chi-square
XRCC1-Arg194Trp TNBC patients (n =70) Controls (n =70) OR (95 % CI)a pb
Number (%) Number (%)
Arg/Arg 20 29 15 21 1.00 Ref
Arg/Trp 31 44 39 56 0.59 (0.26–1.35) 0.301
Trp/Trp 19 27 16 23 0.89 (0.34–2.28) 1.000
Arg 71 51 69 49 1.00 Ref
Trp 69 49 71 51 0.95 (0.59–1.50) 0.920
Table 5 Dependence of geno-
types and frequencies of ERCC2 ,
hOGG1, and XRCC1 gene poly-
morphism alleles on tumor stage
in triple-negative breast cancer
patients (n =70)
a According to the Scarf–Bloom–
Richardson criteria
b Crude odds ratio (confidence in-
terval at 95 %)
c Chi-square
Triple-negative breast cancer patients OR (95 % CI)b pc
Stagea I (n =20) II + III (n=50)
Number (%) Number (%)
ERCC2-Lys751Gln
Lys/Lys 5 (25) 5 (10) 1.00 Ref
Lys/Gln 2 (10) 8 (16) 0.25 (0.03–1.81) 0.175
Gln/Gln 13 (65) 37 (74) 0.35 (0.08–1.41) 0.129
Lys 12 (30) 18 (18) 1.00 Ref
Gln 28 (70) 82 (82) 0.51 (0.21–1.19) 0.182
hOGG1-Ser326Cys
Ser/Ser 3 (15) 13 (26) 1.00 Ref
Ser/Cys 14 (70) 25 (50) 2.42 (0.58–9.99) 0.177
Cys/Cys 3 (15) 12 (24) 1.09 (0.29–4.08) 0.588
Ser 20 (50) 51 (51) 1.00 Ref
Cys 20 (50) 49 (49) 1.08 (0.18–6.43) 0.640
XRCC1-Arg194Trp
Arg/Arg 5 (25) 15 (30) 1.00 Ref
Arg/Trp 12 (60) 19 (38) 1.89 (0.54–6.57) 0.479
Trp/Trp 3 (15) 16 (32) 0.56 (0.11–2.77) 0.377
Arg 22 (55) 49 (49) 1.00 Ref
Trp 18 (45) 51 (51) 0.78 (0.37–1.64) 0.646
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gland, endometrium, bone, cardiovascular system, brain, and
urogenital tract in men and women, with the intracellular
estrogen functioning as a hormone-dependent transcriptional
regulator. Estrogen metabolism in eukaryotic cells includes
formation of a variety of intermediate forms and production of
ROS [31].
BER is very important for repairing base damage induced
by ROS. In our study, we analyzed the association between
polymorphisms of two genes of BER and TNBC.
In the literature, much research suggests that Ser326Cys
polymorphism of hOGG1 gene may contribute to mammary
carcinogenesis [32–34]. However, the reported results have
rather been inconsistent [35–37]. What is important is that
recent reports introduce the role of Ser326Cys polymorphism
in the development of TNBC [34].
In the recent studies, Ser326Cys polymorphism of hOGG1
may be associated with an elevated tumor risk in the Chinese
populations, regarding TNBC [28], while there are still no
data, which would be illustrating the significance of hOGG1
polymorphism for TNBC development in other populations.
In the reported study, the Ser326Cys polymorphism of
hOGG1 gene was not correlated with triple-negative breast
carcinoma progression.
Literature data suggest a protective role of the Trp/Trp
genotype of the Arg/Trp polymorphism of the XRCC1 gene
against the development of cancer, and this function can be
underlined by increasing the activity of BER [27, 38]. In the
literature, many reports confirm the significance of XRCC1-
Arg194Trp polymorphism, regarding the risk of breast carci-
noma [39–42]. This is not in agreement with our result. In the
present work, no significant associations were observed be-
tween Arg194Trp genotype of XRCC1 and the incidence of
TNBC in the Polish women.
In conclusion, in the present study, an association
was identified between Lys751Gln polymorphism of
ERCC2 and the incidence of TNBC. The obtained data
suggest that the reported study may be the first obser-
vation of the polymorphisms in ERCC2 , hOGG1 , and
XRCC1 genes, involved in the DNA repair pathway, to
be associated with triple-negative breast carcinoma risk
in the population of Polish women. Further studies,
conducted on a larger group, are suggested to clarify
this point.
Conflicts of interest None
Table 6 RAD51 , XRCC2 , and XRCC3 gene polymorphism and triple-negative breast cancer progressiona
TNBC patients (n =70) OR (95 % CI)a TNBC patients (n=70) OR (95 % CI)b
Tumor size Node status
T3 + T4 (N=22) T1 + T2 (N =48) N+ (n =38) N− (n =32)
Number (%) Number (%) Number (%) Number (%)
ERCC2-Lys751Gln
Lys/Lys 1 (5) 9 (19) 1.00 Ref 5 (13) 5 (16) 1.00 Ref
Lys/Gln 1 (5) 9 (19) 1.00 (0.05–18.57) 3 (8) 7 (22) 0.42 (0.06–2.48)
Gln/Gln 20 (90) 30 (62) 6.00 (0.70–51.10) 30 (79) 20 (32) 1.50 (0.38–5.85)
Lys 3 (7) 27 (28) 1.00 Ref 13 (17) 17 (27) 1.00 Ref
Gln 41 (93) 69 (72) 5.34 (1.52–18.73) 63 (83) 47 (73) 1.75 (0.77–3.96)
hOGG1-Ser326Cys
Ser/Ser 7 (32) 9 (19) 1.00 Ref 11 (29) 5 (16) 1.00 Ref
Ser/Cys 8 (36) 31 (64) 0.33 (0.09–1.16) 16 (42) 23 (72) 0.31 (0.09–1.38)
Cys/Cys 7 (32) 8 (17) 1.12 (0.27–4.63) 11 (29) 4 (12) 1.25 (0.26–5.93)
Ser 22 (50) 49 (51) 1.00 Ref 38 (50) 33 (52) 1.00 Ref
Cys 22 (50) 47 (49) 1.04 (0.51–2.12) 38 (50) 31 (48) 1.06 (0.54–2.07)
XRCC1-Arg194Trp
Arg/Arg 8 (36) 12 (25) 1.00 Ref 12 (32) 8 (25) 1.00 Ref
Arg/Trp 9 (41) 22 (46) 0.61 (0.18–2.00) 14 (36) 17 (53) 0.54 (0.17–1.71)
Trp/Trp 5 (23) 14 (29) 0.53 (0.13–2.08) 12 (32) 7 (22) 1.14 (0.41–4.16)
Arg 25 (56) 46 (48) 1.00 Ref 38 (50) 33 (52) 1.00 Ref
Trp 19 (44) 50 (52) 0.70 (0.34–1.43) 38 (50) 31 (48) 1.06 (0.54–2.07)
a T2 vs. T3 + T4
bN− (node negative) vs. N+ (node positive)
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